Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042.

Hermida-Prado F, Villaronga MÁ, Granda-Díaz R, Del-Río-Ibisate N, Santos L, Hermosilla MA, Oro P, Allonca E, Agorreta J, Garmendia I, Tornín J, Perez-Escuredo J, Fuente R, Montuenga LM, Morís F, Rodrigo JP, Rodríguez R, García-Pedrero JM.

J Clin Med. 2019 Aug 2;8(8). pii: E1157. doi: 10.3390/jcm8081157.

2.

YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.

Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, Ferrer I, Behrens C, Cuadrado M, Paz-Ares L, Bustelo XR, Gil-Bazo I, Alameda D, Lecanda F, Calvo A, Felip E, Sánchez-Céspedes M, Wistuba II, Granda-Diaz R, Rodrigo JP, García-Pedrero JM, Pio R, Montuenga LM, Agorreta J.

Am J Respir Crit Care Med. 2019 Oct 1;200(7):888-899. doi: 10.1164/rccm.201807-1292OC.

PMID:
31166114
3.

Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer.

Elgendy M, Fusco JP, Segura V, Lozano MD, Minucci S, Echeveste JI, Gurpide A, Andueza M, Melero I, Sanmamed MF, Ruiz MR, Calvo A, Pascual JI, Velis JM, Miñana B, Valle RD, Pio R, Agorreta J, Abengozar M, Colecchia M, Brich S, Renne SL, Guruceaga E, Patiño-García A, Perez-Gracia JL.

Int J Cancer. 2019 Oct 1;145(7):1991-2001. doi: 10.1002/ijc.32256. Epub 2019 Mar 30.

PMID:
30848481
4.

5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging.

Martínez-Terroba E, Behrens C, Agorreta J, Monsó E, Millares L, Felip E, Rosell R, Ramirez JL, Remirez A, Torre W, Gil-Bazo I, Idoate MA, de-Torres JP, Pio R, Wistuba II, Pajares MJ, Montuenga LM.

Thorax. 2019 Apr;74(4):371-379. doi: 10.1136/thoraxjnl-2018-212194. Epub 2018 Nov 24.

PMID:
30472670
5.

The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer.

Martínez-Terroba E, Ezponda T, Bértolo C, Sainz C, Remírez A, Agorreta J, Garmendia I, Behrens C, Pio R, Wistuba II, Montuenga LM, Pajares MJ.

Lab Invest. 2018 Dec;98(12):1562-1574. doi: 10.1038/s41374-018-0128-2. Epub 2018 Sep 4.

6.

The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.

Abou Faycal C, Brambilla E, Agorreta J, Lepeltier N, Jacquet T, Lemaître N, Emadali A, Lucas A, Lacal PM, Montuenga L, Pio R, Gazzeri S, Eymin B.

Br J Cancer. 2018 Jun;118(12):1596-1608. doi: 10.1038/s41416-018-0128-4. Epub 2018 May 24.

7.

A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.

Martínez-Terroba E, Behrens C, de Miguel FJ, Agorreta J, Monsó E, Millares L, Sainz C, Mesa-Guzman M, Pérez-Gracia JL, Lozano MD, Zulueta JJ, Pio R, Wistuba II, Montuenga LM, Pajares MJ.

J Pathol. 2018 Aug;245(4):421-432. doi: 10.1002/path.5096. Epub 2018 Jun 20.

8.

Complement C4d-specific antibodies for the diagnosis of lung cancer.

Ajona D, Okrój M, Pajares MJ, Agorreta J, Lozano MD, Zulueta JJ, Verri C, Roz L, Sozzi G, Pastorino U, Massion PP, Montuenga LM, Blom AM, Pio R.

Oncotarget. 2017 Dec 26;9(5):6346-6355. doi: 10.18632/oncotarget.23690. eCollection 2018 Jan 19.

9.

Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects.

Ajona D, Zandueta C, Corrales L, Moreno H, Pajares MJ, Ortiz-Espinosa S, Martínez-Terroba E, Perurena N, de Miguel FJ, Jantus-Lewintre E, Camps C, Vicent S, Agorreta J, Montuenga LM, Pio R, Lecanda F.

Am J Respir Crit Care Med. 2018 May 1;197(9):1164-1176. doi: 10.1164/rccm.201703-0660OC.

10.

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K.

Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12.

11.

A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.

Ajona D, Ortiz-Espinosa S, Moreno H, Lozano T, Pajares MJ, Agorreta J, Bértolo C, Lasarte JJ, Vicent S, Hoehlig K, Vater A, Lecanda F, Montuenga LM, Pio R.

Cancer Discov. 2017 Jul;7(7):694-703. doi: 10.1158/2159-8290.CD-16-1184. Epub 2017 Mar 13.

12.

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.

Azpilikueta A, Agorreta J, Labiano S, Pérez-Gracia JL, Sánchez-Paulete AR, Aznar MA, Ajona D, Gil-Bazo I, Larrayoz M, Teijeira A, Rodriguez-Ruiz ME, Pio R, Montuenga LM, Melero I.

J Thorac Oncol. 2016 Apr;11(4):524-36. doi: 10.1016/j.jtho.2016.01.013. Epub 2016 Feb 1.

13.

Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations.

Aramburu A, Zudaire I, Pajares MJ, Agorreta J, Orta A, Lozano MD, Gúrpide A, Gómez-Román J, Martinez-Climent JA, Jassem J, Skrzypski M, Suraokar M, Behrens C, Wistuba II, Pio R, Rubio A, Montuenga LM.

BMC Genomics. 2015 Oct 6;16:752. doi: 10.1186/s12864-015-1935-0.

14.

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism-related genes.

Pio R, Agorreta J, Montuenga LM.

J Thorac Cardiovasc Surg. 2015 Oct;150(4):986-92.e1-11. doi: 10.1016/j.jtcvs.2015.06.001. Epub 2015 Jun 9.

15.

Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients.

Grbesa I, Pajares MJ, Martínez-Terroba E, Agorreta J, Mikecin AM, Larráyoz M, Idoate MA, Gall-Troselj K, Pio R, Montuenga LM.

PLoS One. 2015 Apr 27;10(4):e0124670. doi: 10.1371/journal.pone.0124670. eCollection 2015.

16.

The diverse lives of TRAP1.

Agorreta J, Hu J, Pezzella F.

Oncoscience. 2014 Sep 22;1(9):560-1. eCollection 2014. No abstract available.

17.

TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC.

Agorreta J, Hu J, Liu D, Delia D, Turley H, Ferguson DJ, Iborra F, Pajares MJ, Larrayoz M, Zudaire I, Pio R, Montuenga LM, Harris AL, Gatter K, Pezzella F.

Mol Cancer Res. 2014 May;12(5):660-9. doi: 10.1158/1541-7786.MCR-13-0481. Epub 2014 Feb 24.

18.

Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype.

Larrayoz M, Pio R, Pajares MJ, Zudaire I, Ajona D, Casanovas O, Montuenga LM, Agorreta J.

EMBO Mol Med. 2014 Apr;6(4):539-50. doi: 10.1002/emmm.201303214. Epub 2014 Feb 5.

19.

TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients.

Pajares MJ, Agorreta J, Salvo E, Behrens C, Wistuba II, Montuenga LM, Pio R, Rouzaut A.

Br J Cancer. 2014 Mar 18;110(6):1545-51. doi: 10.1038/bjc.2014.33. Epub 2014 Jan 30.

20.

RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner.

Luis-Ravelo D, Antón I, Zandueta C, Valencia K, Pajares MJ, Agorreta J, Montuenga L, Vicent S, Wistuba II, De Las Rivas J, Lecanda F.

Mol Oncol. 2014 Mar;8(2):196-206. doi: 10.1016/j.molonc.2013.11.001. Epub 2013 Nov 12.

21.

Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.

Ajona D, Pajares MJ, Corrales L, Perez-Gracia JL, Agorreta J, Lozano MD, Torre W, Massion PP, de-Torres JP, Jantus-Lewintre E, Camps C, Zulueta JJ, Montuenga LM, Pio R.

J Natl Cancer Inst. 2013 Sep 18;105(18):1385-93. doi: 10.1093/jnci/djt205. Epub 2013 Aug 12.

22.

Individual nodule tracking in micro-CT images of a longitudinal lung cancer mouse model.

Rudyanto RD, Bastarrika G, de Biurrun G, Agorreta J, Montuenga LM, Ortiz-de-Solorzano C, Muñoz-Barrutia A.

Med Image Anal. 2013 Dec;17(8):1095-105. doi: 10.1016/j.media.2013.07.002. Epub 2013 Jul 19.

PMID:
23920346
23.

Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment.

Freire J, Ajona D, de Biurrun G, Agorreta J, Segura V, Guruceaga E, Bleau AM, Pio R, Blanco D, Montuenga LM.

Neoplasia. 2013 Aug;15(8):913-24.

24.

Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.

Oliemuller E, Peláez R, Garasa S, Pajares MJ, Agorreta J, Pío R, Montuenga LM, Teijeira A, Llanos S, Rouzaut A.

Int J Cancer. 2013 May 1;132(9):1986-95. doi: 10.1002/ijc.27881. Epub 2012 Oct 20.

25.

Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma.

Antón I, Molina E, Luis-Ravelo D, Zandueta C, Valencia K, Ormazabal C, Martínez-Canarias S, Perurena N, Pajares MJ, Agorreta J, Montuenga LM, Segura V, Wistuba II, De Las Rivas J, Hermida J, Lecanda F.

Am J Respir Crit Care Med. 2012 Jul 1;186(1):96-105. doi: 10.1164/rccm.201110-1826OC. Epub 2012 Mar 29.

26.

Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.

Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, Torre W, Lozano MD, Brambilla E, Brambilla C, Wistuba II, Behrens C, Timsit JF, Pio R, Field JK, Montuenga LM.

J Clin Oncol. 2012 Apr 1;30(10):1129-36. doi: 10.1200/JCO.2011.37.4231. Epub 2012 Feb 21.

27.

Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis.

Valencia K, Ormazábal C, Zandueta C, Luis-Ravelo D, Antón I, Pajares MJ, Agorreta J, Montuenga LM, Martínez-Canarias S, Leitinger B, Lecanda F.

Clin Cancer Res. 2012 Feb 15;18(4):969-80. doi: 10.1158/1078-0432.CCR-11-1686. Epub 2012 Jan 5.

28.

Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance.

Ponz-Sarvisé M, Nguewa PA, Pajares MJ, Agorreta J, Lozano MD, Redrado M, Pio R, Behrens C, Wistuba II, García-Franco CE, García-Foncillas J, Montuenga LM, Calvo A, Gil-Bazo I.

Clin Cancer Res. 2011 Jun 15;17(12):4155-66. doi: 10.1158/1078-0432.CCR-10-3381. Epub 2011 May 3.

29.

VEGF₁₂₁b and VEGF₁₆₅b are weakly angiogenic isoforms of VEGF-A.

Catena R, Larzabal L, Larrayoz M, Molina E, Hermida J, Agorreta J, Montes R, Pio R, Montuenga LM, Calvo A.

Mol Cancer. 2010 Dec 31;9:320. doi: 10.1186/1476-4598-9-320.

30.

The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression.

Ezponda T, Pajares MJ, Agorreta J, Echeveste JI, López-Picazo JM, Torre W, Pio R, Montuenga LM.

Clin Cancer Res. 2010 Aug 15;16(16):4113-25. doi: 10.1158/1078-0432.CCR-10-0076. Epub 2010 Aug 3.

31.

Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer.

Pio R, Blanco D, Pajares MJ, Aibar E, Durany O, Ezponda T, Agorreta J, Gomez-Roman J, Anton MA, Rubio A, Lozano MD, López-Picazo JM, Subirada F, Maes T, Montuenga LM.

BMC Genomics. 2010 Jun 3;11:352. doi: 10.1186/1471-2164-11-352.

32.

TGFBI expression is associated with a better response to chemotherapy in NSCLC.

Irigoyen M, Pajares MJ, Agorreta J, Ponz-Sarvisé M, Salvo E, Lozano MD, Pío R, Gil-Bazo I, Rouzaut A.

Mol Cancer. 2010 May 28;9:130. doi: 10.1186/1476-4598-9-130.

33.

Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases.

Liu D, Hu J, Agorreta J, Cesario A, Zhang Y, Harris AL, Gatter K, Pezzella F.

Cancer Lett. 2010 Oct 28;296(2):194-205. doi: 10.1016/j.canlet.2010.04.017. Epub 2010 May 14.

PMID:
20471161
34.

microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells.

Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, Zarate R, Diaz-Gonzalez JA, Ramirez N, Sola JJ, Jimenez P, Rodriguez J, Garcia-Foncillas J.

Clin Cancer Res. 2009 Apr 1;15(7):2281-90. doi: 10.1158/1078-0432.CCR-08-1818. Epub 2009 Mar 24.

35.

Identification of importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens.

Nguewa PA, Agorreta J, Blanco D, Lozano MD, Gomez-Roman J, Sanchez BA, Valles I, Pajares MJ, Pio R, Rodriguez MJ, Montuenga LM, Calvo A.

BMC Mol Biol. 2008 Nov 17;9:103. doi: 10.1186/1471-2199-9-103.

36.

Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates.

Zudaire I, Lozano MD, Vazquez MF, Pajares MJ, Agorreta J, Pio R, Zulueta JJ, Yankelevitz DF, Henschke CI, Montuenga LM.

Histol Histopathol. 2008 Jan;23(1):33-40. doi: 10.14670/HH-23.33.

37.

Molecular profiling of computed tomography screen-detected lung nodules shows multiple malignant features.

Pajares MJ, Zudaire I, Lozano MD, Agorreta J, Bastarrika G, Torre W, Remírez A, Pio R, Zulueta JJ, Montuenga LM.

Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):373-80.

38.

Adrenomedullin expression in a rat model of acute lung injury induced by hypoxia and LPS.

Agorreta J, Zulueta JJ, Montuenga LM, Garayoa M.

Am J Physiol Lung Cell Mol Physiol. 2005 Mar;288(3):L536-45. Epub 2004 Dec 3.

39.

Effects of acute hypoxia and lipopolysaccharide on nitric oxide synthase-2 expression in acute lung injury.

Agorreta J, Garayoa M, Montuenga LM, Zulueta JJ.

Am J Respir Crit Care Med. 2003 Aug 1;168(3):287-96. Epub 2003 May 28.

Supplemental Content

Loading ...
Support Center